• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Electromed Inc.

    11/30/23 4:17:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ELMD alert in real time by email
    S-8 POS 1 elmd231218_s8pos.htm FORM S-8 POS

     

    As filed with the Securities and Exchange Commission on November 30, 2023

     

    Registration No. 333-221895

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION 

    Washington, DC 20549

     

    Post-Effective Amendment No. 1

    to
    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE

    Securities Act of 1933

     

     ELECTROMED, INC.

    (Exact name of registrant as specified in its charter)

     

    Minnesota   41-1732920
    (State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

    500 Sixth Avenue NW

    New Prague, Minnesota

      56071
    (Address of Principal Executive Offices)   (Zip Code)

     

    ELECTROMED, INC. 2017 OMNIBUS INCENTIVE PLAN

    ELECTROMED, INC. 2023 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

    Bradley M. Nagel

    Chief Financial Officer

    Electromed, Inc.

    500 Sixth Avenue NW

    New Prague, Minnesota 56071

    (952) 758-9299 

    (Name, address and telephone number, including area code, of agent for service)

     

    Copy to: 

    Joshua L. Colburn and Ryan R. Woessner 

    Faegre Drinker Biddle & Reath LLP  

    2200 Wells Fargo Center  

    90 South Seventh Street  

    Minneapolis, Minnesota 55402  

    (612) 766-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ 

     

    Accelerated filer ☐ 

    Non-accelerated filer ☒  

    Smaller reporting company ☒ 

    Emerging growth company ☐ 

         

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY STATEMENT

     

    On December 4, 2017, Electromed, Inc. (the “Registrant”) filed a Registration Statement on Form S-8 (File No. 333-221895) (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) to register 900,000 shares of the Registrant’s common stock, par value $0.01 per share (the “Common Stock”), issuable under the Electromed, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”).

     

    The shareholders of the Registrant approved the Electromed, Inc. 2023 Equity Incentive Plan (the “2023 Plan”) on November 10, 2023 (the “Effective Date”) and, in connection therewith, no further awards will be made under the 2017 Plan. As of the Effective Date, there were 192,018 shares of Common Stock, that were authorized to be awarded under the 2017 Plan but that, as of that date, were not issued or subject to outstanding awards granted under the 2017 Plan. Accordingly, as a result of the approval of the 2023 Plan (the “Prior Plan Shares”), these Prior Plan Shares are no longer available for new awards under the 2017 Plan and will not be issued under the 2017 Plan. Under the terms of the 2023 Plan, the Registrant may issue up to 850,000 shares of Common Stock, plus the Prior Plan Shares. In addition, up to 360,856 shares of Common Stock subject to outstanding awards granted under the 2017 Plan that were outstanding as of November 10, 2023, to the extent that, on or after the Effective Date, such awards expire, are cancelled, are forfeited or are settled for cash, shall become eligible for issuance under the 2023 Plan (together with the Prior Plan Shares, the “Carryover Shares”).

     

    Accordingly, pursuant to the undertaking in Item 512(a)(1)(iii) of Regulation S-K that the Registrant disclose a material change in the plan of distribution as it was originally disclosed in the Registration Statement, the Registrant is filing this Post-Effective Amendment No. 1 to the Registration Statement to register the offer of the Carryover Shares under the 2023 Plan and reflect that the Carryover Shares available for issuance under the Registration Statement may be issued and sold under the 2023 Plan (as such shares would no longer be issuable under the 2017 Plan as of the effective date of the 2023 Plan).

     

    Contemporaneously with the filing of this Post-Effective Amendment No. 1 to the Registration Statement, the Registrant is filing a Registration Statement on Form S-8 to register the 850,000 shares of Common Stock authorized for issuance pursuant to the 2023 Plan, which amount excludes the Carryover Shares. No additional Common Stock are being registered by this Post-Effective Amendment No. 1 to the Registration Statement.

     

    Except to the extent specified herein, the Registration Statement as previously filed is not amended or otherwise affected by this Post-Effective Amendment thereto.

     

    PART I

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this registration statement:

     

      (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the Commission on August 22, 2023 (the “Annual Report”), including the portions of the Company’s Definitive Proxy Statement on Schedule 14A for its 2023 Annual Meeting of Shareholders, filed with the Commission on September 26, 2023, incorporated by reference into the Annual Report;
         
      (b) The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023, filed with the Commission on November 7, 2023;
         
      (c) The Registrant’s Current Report on Form 8-K filed with the Commission on November 15, 2023;
         
      (d)

    All other reports filed by the Registrant with the Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since June 30, 2023 (other than information deemed to have been “furnished” rather than “filed” in accordance with the Commission’s rules); and

         
      (e)

    The description of the Registrant’s capital stock contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019, filed with the Commission on August 27, 2019, including any amendment or report filed for the purpose of updating such description.

         

    In addition, all reports and other documents subsequently filed, but not furnished, by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this registration statement that indicates that all of the shares of Common Stock offered hereby have been sold or that deregisters all shares of the Common Stock then remaining unsold, shall be deemed to be incorporated by reference in and a part of this registration statement from the date of filing of such reports and documents, except as to any document, or portion of or exhibit to a document, that is “furnished” to (rather than “filed” with) the Commission.

     

     

     

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in this registration statement shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in this registration statement or in any other subsequently filed document that also is or is deemed to be incorporated by reference in this registration statement modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

       

    Item 8.    Exhibits

     

    Exhibit
    Number

    Description

     

    4.1 Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)
       
    4.2 Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)
       
    4.3 Electromed, Inc. 2017 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to Registration Statement on Form S-8 filed on December 4, 2017)
       
    4.4 Electromed, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 4.3 to Registration Statement on Form S-8 filed on November 30, 2023)
       
    5.1 Opinion of Faegre Drinker Biddle & Reath LLP (f/k/a Faegre Baker Daniels LLP) with respect to the legality of the securities registered with respect to the 2017 Plan*
       
    5.2 Opinion of Faegre Drinker Biddle & Reath LLP with respect to the legality of the securities being registered with respect to the 2023 Plan
       
    23.1 Consent of RSM US LLP
       
    23.2 Consent of Faegre Drinker Biddle & Reath (f/k/a Faegre Baker Daniels LLP) (included in its opinion filed as Exhibit 5.1)
       
    23.3 Consent of Faegre Drinker Biddle & Reath (included in its opinion filed as Exhibit 5.2)
       
    24.1 Powers of Attorney (included on signature page hereof)
       
    * Previously Filed

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Prague, State of Minnesota, on November 30, 2023.

     

      ELECTROMED, INC.
      By: /s/ James L. Cunniff
        James L. Cunniff
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature to this Registration Statement appears below hereby constitutes and appoints James L. Cunniff and Bradley M. Nagel, and each of them, his, her or their true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for him, her or their and in his, her or their name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, in connection with the registration under the Securities Act of common stock of said Registrant to be issued pursuant to the Electromed, Inc. 2017 Omnibus Incentive Plan or 2023 Equity Incentive Plan, granting unto said attorneys-in-fact and agents and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he, she or they might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title Date
           
    /s/ James L. Cunniff   President and Chief Executive Officer and Director November 30, 2023
    James L. Cunniff   (Principal Executive Officer)  
           
    /s/ Bradley M. Nagel   Chief Financial Officer (Principal Financial Officer November 30, 2023
    Bradley M. Nagel   and Principal Accounting Officer)  
           
    /s/ Stan K. Erickson   Director November 30, 2023
    Stan K. Erickson      
           
    /s/ Gregory J. Fluet   Director November 30, 2023
    Gregory J. Fluet      
           
    /s/ Joseph L. Galatowitsch   Director November 30, 2023
    Joseph L. Galatowitsch      
           
    /s/ Kathleen S. Skarvan   Director November 30, 2023
    Kathleen S. Skarvan      
           
    /s/ Andrew J. Summers   Director November 30, 2023
    Andrew J. Summers      
           
    /s/ Kathleen A. Tune   Director November 30, 2023
    Kathleen A. Tune      
           
    /s/ Andrea M. Walsh   Director November 30, 2023
    Andrea M. Walsh      

     

     

    Get the next $ELMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELMD

    DatePrice TargetRatingAnalyst
    8/27/2025$36.00Buy
    Lake Street
    7/22/2025$29.00Buy
    Roth Capital
    2/20/2025$38.00Buy
    B. Riley Securities
    More analyst ratings

    $ELMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tune Kathleen A was granted 3,000 shares, increasing direct ownership by 25% to 15,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:16:07 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Erickson Stan K. was granted 3,000 shares, increasing direct ownership by 8% to 38,817 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:12:20 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Fluet Gregory was granted 3,000 shares, increasing direct ownership by 17% to 21,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/3/25 8:11:51 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    SEC Filings

    View All

    Electromed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Electromed, Inc. (0001488917) (Filer)

    12/18/25 4:46:08 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Electromed, Inc. (0001488917) (Filer)

    11/18/25 4:17:35 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Electromed Inc.

    10-Q - Electromed, Inc. (0001488917) (Filer)

    11/12/25 4:11:47 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Electromed with a new price target

    Lake Street resumed coverage of Electromed with a rating of Buy and set a new price target of $36.00

    8/27/25 8:41:37 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Roth Capital initiated coverage on Electromed with a new price target

    Roth Capital initiated coverage of Electromed with a rating of Buy and set a new price target of $29.00

    7/22/25 7:52:34 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on Electromed with a new price target

    B. Riley Securities initiated coverage of Electromed with a rating of Buy and set a new price target of $38.00

    2/20/25 7:01:40 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Cunniff James L. bought $137,250 worth of shares (9,000 units at $15.25), increasing direct ownership by 900% to 10,000 units (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    3/5/24 4:49:02 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Summers Andrew bought $302,368 worth of shares (28,797 units at $10.50) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    12/18/23 4:44:26 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Cunniff James L. bought $10,560 worth of shares (1,000 units at $10.56) (SEC Form 4)

    4 - Electromed, Inc. (0001488917) (Issuer)

    11/22/23 4:01:43 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Financials

    Live finance-specific insights

    View All

    Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live webcast of the call will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Electrome

    1/27/26 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. Announces First Quarter Fiscal 2026 Results

    Strong operational execution results in twelfth consecutive quarter of year-over-year revenue and net income growth Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended September 30, 2025 ("Q1 FY 2026"). Q1 FY 2026 Company Highlights Net revenues increased 15.1% to $16.9 million in Q1 FY 2026, from $14.7 million in the first quarter of the prior fiscal year. Operating income increased to $2.7 million, a 37.8% increase from the first quarter of the prior fiscal year. Net income was $2.1 million, or $0.25 per diluted share, representing an increase of 44.9%, compared to

    11/12/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 first quarter ended September 30, 2025, on Wednesday, November 12, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed's website and directly via the following link: Ele

    10/29/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Leadership Updates

    Live Leadership Updates

    View All

    Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes

    Electromed, Inc. ("Electromed" or the "Company") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Electromed is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Jim Cunniff, Electromed's President and Chief Executive Off

    5/27/25 4:05:00 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed, Inc., Appoints Peter Horwich, Vice President, Marketing

    Key hire will drive the Company's market development and therapy adoption initiatives Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Peter Horwich as Vice President, Marketing. Mr. Horwich, an accomplished marketing veteran, brings over 20 years of experience in driving commercial growth in the Medical Technology market to Electromed. Prior to joining Electromed, Horwich directed Global Strategic Marketing for Respiratory Therapies at Abiomed (now J&J MedTech), a Medical Device manufacturer of extracorporeal membrane oxygenation (ECMO) lung recovery systems, where he was responsible for global marketing

    10/28/24 8:30:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Electromed Names Jim Cunniff as President and Chief Executive Officer

    Healthcare Executive Brings More Than 30 Years of Executive Experience and Commercial Success to Electromed Electromed, Inc. ("Electromed") (NYSE:ELMD), a leader in innovative airway clearance technologies, today announced the appointment of Jim Cunniff as its new President and Chief Executive Officer (CEO), effective July 1, 2023. Mr. Cunniff will also join Electromed's Board of Directors. "We are pleased to announce the appointment of Jim Cunniff as president and CEO," said Lee Jones, Chair of the Board. "Jim is a proven executive with deep experience driving growth and profitability through excellence in products and services that benefit patients and support care teams. "As Kathle

    6/5/23 8:15:00 AM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ELMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Electromed Inc.

    SC 13D/A - Electromed, Inc. (0001488917) (Subject)

    11/21/24 4:09:11 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/13/24 5:42:25 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Electromed Inc.

    SC 13G/A - Electromed, Inc. (0001488917) (Subject)

    11/12/24 4:09:16 PM ET
    $ELMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care